Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Guanine nucleotide-binding protein G(t) subunit alpha-1 (GNAT1) is the rod-specific alpha subunit of the heterotrimeric G protein complex known as transducin, which is found in retinal rod photoreceptor cells. It plays a central role in the phototransduction cascade, coupling the activation of rhodopsin by light to downstream effectors that generate electrical signals, ultimately enabling vision in low-light conditions. When activated by rhodopsin, GNAT1 promotes GTP binding, dissociates from the G protein complex, and activates cGMP-phosphodiesterase (cGMP-PDE), initiating signal transduction processes necessary for vision. Mutations in this gene can cause autosomal dominant congenital stationary night blindness due to disruption of this signaling pathway[1][2][3][6]. GNAT1 is not presently known to be a direct pharmacological drug target, being primarily studied for its fundamental role in vision and as a genetic cause of retinal diseases rather than as a tractable therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Guanine nucleotide-binding protein G(t) subunit alpha-1 (GNAT1).